CN102166294A - Common anemarrhena polysaccharide extractive and preparation method and medicinal purposes thereof - Google Patents
Common anemarrhena polysaccharide extractive and preparation method and medicinal purposes thereof Download PDFInfo
- Publication number
- CN102166294A CN102166294A CN 201110087706 CN201110087706A CN102166294A CN 102166294 A CN102166294 A CN 102166294A CN 201110087706 CN201110087706 CN 201110087706 CN 201110087706 A CN201110087706 A CN 201110087706A CN 102166294 A CN102166294 A CN 102166294A
- Authority
- CN
- China
- Prior art keywords
- extract
- anemaran
- polysaccharide
- precipitation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a common anemarrhena polysaccharide extractive and a preparation method and medicine purposes thereof. The preparation method comprising the steps of degreasing raw materials, extracting the degreased raw materials with water, precipitating the extracted material with alcohol to obtain crude polysaccharide, carrying out dialysis and ion-exchange column chromatography on the crude polysaccharide to eliminate proteins, pigments and molecular chemical components to produce a high-purity common anemarrhena polysaccharide extractive. The content of the common anemarrhena polysaccharide in the extractive provided by the invention accounts for more than 60 weight percent of the common anemarrhena extractive in terms of glucose. A huge amount of pharmacological experiments prove that common anemarrhena polysaccharide has an immunodepression activity and has the medical purposes of treating proinflammatory traumatic diseases, such as nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes.
Description
Technical field
The present invention relates to a kind of anemaran extract and its preparation method, and with this anemaran extract as immunosuppressive activity, be used for the treatment of the immunoinflammatory injury disease: the medical usage of nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes.
Background technology
The Rhizoma Anemarrhenae is the Liliaceae Anemarrhena plant Rhizoma Anemarrhenae (Anemarrhena asphodeloides Bge.) rhizome, and nature and flavor hardship, sweet, cold is returned lung, stomach, kidney channel.Have clearing away heat-fire, nourshing Yin and drynsessmoistening prescription function, be used for fever caused by exogenous pathogenic factors, the hyperpyrexia excessive thirst, lung-heat type cough, osteopyrexia and fever, interior-heat is quenched one's thirst, the dryness of the intestine constipation.Chemical constituent in the modern study discovery Rhizoma Anemarrhenae is based on steroidal saponin, two benzene pyrrones, lignanoids, flavonoid, organic acid etc. are still arranged, it is one of focus medicine in the modern medicine research, progress in recent years is rapid, but mostly concentrate on timosaponin class, the two benzene pyrrones composition, think that timosaponin is the important effective substance of the Rhizoma Anemarrhenae, less to anemaran research, do not see that as yet it has the report of immunosuppressive activity.The present invention has invented a kind of new method for preparing anemaran by deep chemistry, pharmacology, pharmacodynamic study, and this method is simple to operate, economical and energy saving, and can obtain the polysaccharide component of higher degree and big content; Simultaneously find that first anemaran has immunosuppressive activity, can be used for treating and the relevant various diseases of immunoinflammatory damage: nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes.The research of saponins, two benzene pyrrones effective substances is diverse in this and the Rhizoma Anemarrhenae former studies.
Summary of the invention
One of the object of the invention provides a kind of anemaran extract with immunosuppressive activity.
Two of the object of the invention provides a kind of above-mentioned anemaran preparation method of extract, and the content of anemaran accounts for more than 60% of extract weight percentage ratio.
Three of the object of the invention is above-mentioned anemaran extract to be made the immunosuppressant of various dosage forms, is used for the treatment of the immunoinflammatory injury disease: the medical usage of nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
A kind of anemaran preparation method of extract, it is characterized in that: after the defat of Rhizoma Anemarrhenae raw medicinal material, obtain crude polysaccharides through water extraction, alcohol precipitation again, crude polysaccharides is sloughed albumen, pigment through dialysis, ion-exchange chromatography, remove the micromolecule chemical constituent, make the anemaran extract of higher degree.
A kind of method for preparing above-mentioned anemaran extract, it comprises following concrete steps:
(1) with the Rhizoma Anemarrhenae with high concentration ethanol backflow weeding of grease solubility impurity; (2) residue adds the water reflux, extract,, and filtrate concentrates, and adds the ethanol precipitate with ethanol, centrifugal must the precipitation; (3) precipitation is used dehydrated alcohol successively, and acetone washs respectively; (4) precipitation after the washing is redissolved with distilled water, dialysis; (5) dialysis solution concentrates, and adds the ethanol precipitate with ethanol, the centrifugal polysaccharide precipitation that gets; (6) polysaccharide precipitation is used dehydrated alcohol successively, and acetone washs respectively; (7) precipitation after the washing is redissolved with distilled water, and employing weak acid and weak base type anion and cation exchange resin series process is sloughed pigment and the protein in the polysaccharide, promptly gets Rhizoma Anemarrhenae polyoses extract.
In order to reach better extraction effect, preferred, in the step (1) with the Rhizoma Anemarrhenae with 80～95% alcohol reflux defats of 6～12 times of weight 2～3 times, 2～3h refluxes at every turn; The distilled water reflux, extract, 2～3 times that in the step (2) residue is added 6～12 times of weight, each reflux, extract, 2～3h is concentrated into medical material 0.2～1.0 volume with filtrate, adds 80～95% ethanol precipitate with ethanol, centrifugal must the precipitation; To precipitate the dehydrated alcohol of using 2～4 times of weight successively in step (3), (6), acetone washs respectively; Precipitation in the step (4) is redissolved with the distilled water of 0.5～2.0 times of weight, is 3.0 * 10 with the molecular weight size
3-1.2 * 10
4Bag filter dialysis 24～72h.
To from the Rhizoma Anemarrhenae, adopt DEAE-Sepharose F.F and DEAE-52 ion-exchange chromatography (eluting is the NaCl solution of 0.1-1mol/L mutually) successively by isolated polysaccharide, and collect liquid and can select but be not limited to following gelose gel column chromatography to do and be further purified separation: Sephadex G50, Sephacryl S100, Sephacryl 200, Sephacryl S300 and Sephacryl S400 (eluting is 0.1-1mol/L NaCl solution mutually).The content of total polysaccharides accounts for more than 60% of extract weight percentage ratio in the anemaran extract of the present invention, is further purified even can obtains the anemaran monomer.
Described anemaran extract has immunosuppressive activity: the mouse monokaryon macrophage phagocytic function is inhibitory action, and prompting has the nonspecific immunity inhibit feature; The content that the experimental rat hemolysin generates due to the reduction sheep red blood cell (SRBC), expression has the humoral immunization inhibit feature.The anemaran extract can be used for treating the immunoinflammatory injury disease: nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes by immunosuppression mechanism.
After anemaran extract of the present invention can add various adjuvants and pharmaceutically acceptable carrier, excipient or diluent required when preparing different dosage form, method of Chinese medicinal with routine is prepared into any suitable clinical preparation, for example can be injection (powder pin, freeze-dried powder, liquid drugs injection, transfusion etc.), oral formulations (tablet, oral liquid, granule, capsule, soft capsule or drop pill) etc.
The specific embodiment
Further describe the present invention below in conjunction with specific embodiment, advantage of the present invention and characteristics will be more clear along with description.But these embodiment only are exemplary, scope of the present invention are not constituted any restriction.It will be understood by those skilled in the art that and down can make amendment or replace without departing from the spirit and scope of the present invention, but these modifications and replacing all fall within the scope of protection of the present invention the details of technical solution of the present invention and form.
Embodiment 1
Get the about 2.8kg of rhizoma ane marrhenae, with 90% alcohol reflux 3 times, each 2h, filter, filtering residue is dried 10 times of amounts of residue adding distil water, reflux, extract, 3 times, each 2h filters, merging filtrate, decompression and solvent recovery be to 1 times of volume of medical material, transfers to 95% ethanol that to contain the alcohol amount be 80%, standing over night, 2000rpm/min is centrifugal, and precipitation with 4 times of amount dehydrated alcohol, washing with acetone, gets total polysaccharides successively.Getting total polysaccharides is dissolved in water, the supernatant flowing water dialysis 48h in the bag filter that packs into, distill water dialysis 24h, dialysis solution is evaporated to medical material 1 volume, add 95% ethanol and transfer that to contain the alcohol amount be 85%, standing over night, 2000rpm/min is centrifugal, precipitation is washed successively with 4 times of amount dehydrated alcohol, acetone, distilled water redissolves, slough pigment and protein lyophilization in the total polysaccharides through weak acid and weak base type anion and cation exchange resin (Amberlite FPA90Cl+Amberlite IRC84), must make with extra care anemaran.Use the phenolsulfuric acid method, at the 500nm place, determined by ultraviolet spectrophotometry total polysaccharides content is with glucose C
6H
12O
6Count 65%.
Embodiment 2
Get the about 3kg of rhizoma ane marrhenae, with 80% alcohol reflux 2 times, each 3h, filter, filtering residue is dried 8 times of amounts of residue adding distil water, reflux, extract, 2 times, each 3h filters, merging filtrate, decompression and solvent recovery be to 1 times of volume of medical material, transfers to 95% ethanol that to contain the alcohol amount be 80%, standing over night, 2000rpm/min is centrifugal, and precipitation with 3 times of amount dehydrated alcohol, washing with acetone, gets total polysaccharides successively.Getting total polysaccharides is dissolved in water, supernatant flowing water dialysis 48h, distill water dialysis 24h, dialysis solution are evaporated to medical material 1 volume, add 95% ethanol and transfer that to contain the alcohol amount be 80%, standing over night, 2000rpm/min is centrifugal, and precipitation is washed successively with 3 times of weight dehydrated alcohol, acetone, and distilled water redissolves, slough pigment and protein lyophilization in the total polysaccharides through weak acid and weak base type anion and cation exchange resin (Amberlite FPA90Cl+Amberlite IRC84), must make with extra care anemaran.Use the phenolsulfuric acid method, at the 500nm place, determined by ultraviolet spectrophotometry total polysaccharides content is with glucose C
6H
12O
6Count 60%.
Embodiment 3 makes infusion solution
Rhizoma Anemarrhenae total polysaccharides is done and is further purified separation through agarose gel post Sephacryl S300, Sephadex G50 chromatograph: obtain the above anemaran extract of 98% purity, add an amount of solubilizing agent, grind, add a small amount of water for injection again and dilute mixing, it is an amount of to add sodium chloride then, add the injection water after the dissolving again to ormal weight, filter embedding, sterilization, promptly.
Embodiment 4 makes tablet
Female polyoses extract of getting is an amount of, adds right amount of auxiliary materials such as diluent, disintegrating agent, and mixing is made granule, drying, and compacting is in blocks, and coating or spray film-coat are promptly.
Experimental example 1 anemaran antiinflammatory experimentation
Get the ICR male mice, be divided into Rhizoma Anemarrhenae high dose (440mg/kg), Rhizoma Anemarrhenae low dosage (110mg/kg), positive control dexamethasone (3.6mg/kg) and blank group immediately.Weigh and respectively organize the mice body weight, the computation of mean values standard deviation is determined no group difference, gastric infusion is three days continuously, the 3rd day 50min after the last administration, every Mus auris dextra are coated with proinflammatory agent (dimethylbenzene 20 μ l), and left ear is as blank, after 3 hours mice is put to death, cut two ears and lay round auricle, analytical balance is weighed, and calculates the mice ear degree.The diversity that compares 4 groups of swelling degree.Experimental result sees Table 1.
Table 1: anemaran antiinflammatory experimental result
Annotate: compare with the blank group
*P＜0.05,
*P＜0.01
Experimental result: each administration group compares with the blank group, the left and right sides ear difference weight saving of Rhizoma Anemarrhenae high and low dose group mice, and it is relevant to be dosage, and high dose group has utmost point significant difference (p＜0.01).Show that the anemaran extract can reduce the mice ear degree, has certain antiinflammatory action.
The research of experimental example 2 anemaran refrigeration functions
Get male 80 of Wistar rat, be divided into Rhizoma Anemarrhenae high dose (308mg/kg), low dosage (77mg/kg), positive control Dexamethasone group (3.78mg/kg) and model control group at random by body weight.Earlier with the normal anus temperature of anus every Mus of temperature instrumentation amount (anus temperature meter inserts anal 1.5cm) secondary, the initial body temperature of mice respectively organized in record, ask its meansigma methods as normal body temperature, the computation of mean values standard deviation is determined no group difference, and fasting be can't help distinguishing gastric infusion and normal saline (model control group) behind the water 12h.Subcutaneous injection 2 behind the gastric infusion 30min, and 2, 4-dinitrophenol (30mg/kg) pyrogenicity is to 0.5 hour, 1 hour, 2 hours, 4 hours and the variation of 6 hour record rat temperatures after the pyrogenicity agent.The results are shown in Table 2.
Table 2: the analgesic experimental result of anemaran
Annotate: each group and blank group are at identical time ratio
*P＜0.05,
*P＜0.01
Experimental result: the normal body temperature of each treated animal does not have evident difference (P＞0.05), obviously raises to each the treated animal body temperature of different time after the pyrogenicity agent.Behind the pyrogenicity 0.5h, each treated animal body temperature obviously raises except that the positive drug Dexamethasone group; Behind the pyrogenicity 1h, each organizes the body temperature no evident difference that all raises; Behind pyrogenicity 2h, the 4h, positive controls, anemaran high and low dose treated animal body temperature obviously reduce; Behind the pyrogenicity 6h, each treated animal body temperature convergence is normal.Show that anemaran can suppress 2, the rat temperature that the 4-dinitrophenol causes raises, and has refrigeration function.
Experimental example 3 anemarans are to the influence of immunosuppressed mice mononuclear-macrophage phagocytic function
Get BALB/C male mice 80, be divided into blank group, Dexamethasone group and the high, medium and low dosage group of the Rhizoma Anemarrhenae at random, 15 every group, blank group gives normal saline, and other are respectively organized administration and see the following form, all to irritate the administration of stomach mode, successive administration 7d.After the last administration 24 hours, inject the india ink 0.1ml/10g of 4 times of 1% gelatin dilution, respectively at getting blood 20 μ l behind 2min and the 6min socket of the eye, and it is joined 0.1%Na through mouse tail vein
2CO
3Shake up among the solution 2ml, with 0.1%Na
2CO
3Do blank, at spectrophotometer 600nm wavelength place's photometry density value, OD
1The optical density value of expression 2min, OD
2The optical density value of expression 6min.Index K is cleaned up in calculating according to formula, and the K value gets phagocytic index α after body weight and the conversion of liver spleen weight.Clean up index K=lgOD
1-lgOD
2/ t
2-t
1, phagocytic index α=body weight/liver spleen weight *
3√ K.Experimental result sees Table 3.
Table 3: anemaran is to the influence of immunosuppressed mice mononuclear-macrophage phagocytic function
Annotate: each group and blank group are at identical time ratio
*P＜0.05,
*P＜0.01
The experimental result Dexamethasone group compares with blank group, cleans up index K value and phagocytic index α value and all obviously reduces, and utmost point significant difference (p＜0.01) is arranged; Rhizoma Anemarrhenae high dose compares with blank group, and K value and α value all descend, K value (p＜0.05), and there were significant differences, and α value (p＜0.01) has utmost point significant difference.Dosage and Rhizoma Anemarrhenae low dosage and blank the group relatively in the Rhizoma Anemarrhenae are cleaned up index K value and phagocytic index α value all descends, and the α value has utmost point significant difference (p＜0.01), and the immunosuppressant index of α value is better than Dexamethasone group.Experimental result shows that anemaran has the nonspecific immunity inhibitory action.
Experimental example 4 anemarans generate the influence test of (colorimetry) to the mice hemolytic antibody
Kunming mouse is divided into 4 groups at random, i.e. blank group, model control group, polysaccharide low dose group and polysaccharide high dose group.Every day, the lumbar injection polysaccharide was 1 time, continuous 14 days.Except that the blank group, all the other are respectively organized every mice and carry out immunity for 8 medicine pneumoretroperitoneum injection sheep red blood cell (SRBC) suspensions 0.2ml/ (about 400,000,000 cells), with normal saline serum is pressed the 1:300 dilution proportion, with the mice serum 1.0ml after the dilution, sheep red blood cell (SRBC) 0.5ml, add in the test tube, add guinea pig serum 1.0ml again through normal saline 1:10 dilution, blank is with equal-volume physiologic saline for substitute mice serum, put test tube in 37 ℃ of water-bath 10min, take out test tube and place ice-water bath, with cessation reaction, the cooling back is centrifugal.With centrifugal back supernatant 1.0ml, Dou Shi liquid 3.0ml adds in the test tube, and static 10min behind the mixing measures the trap value at the 540nm place.Trap value when in a test tube, adding 0.25ml sheep red blood cell (SRBC) and Dou Shi liquid 3.75ml mensuration sheep red blood cell (SRBC) HD50 in addition.
The half hemolysis value HC of sample
50Trap value during=absorption of sample degree value X serum diluting multiple/sheep red blood cell (SRBC) HD50.Statistical method: all data mean ± SD represent, relatively check with t between group.Test and the results are shown in Table 4.
Table 4: the influence that the mice hemolytic antibody generates
Annotate:
△ △Expression is compared P＜0.01 with blank group;
*Expression is compared P＜0.05 with model control group;
*Expression is compared P＜0.01 with model control group
Experimental result: model group and blank group relatively have utmost point significant difference (P＜0.01), show the modeling success.Anemaran low dosage and model group relatively have significant difference (P＜0.05), and anemaran high dose and model group relatively have utmost point significant difference (P＜0.01).Experimental result shows that anemaran generates hemolysin due to the sheep red blood cell (SRBC) and has certain inhibitory action, illustrates to have the humoral immunization inhibit feature.
Experimental example 5 anemaran extracts are to the drug action of chronic glomerulonephritis rat
Get the SD rat, be divided into blank group, model control group, polysaccharide low dose group, polysaccharide high dose group at random, 10 every group.Get the 70mg rabbit igg and be dissolved in the 10ml normal saline, with 60ml Freund mixing, make Emulsion, except that the blank group, every rat gives 1ml, and the multiple spot subcutaneous injection is pre-immunity.Pre-immunity back the 7th day and the 8th day, tail vein injection dilutes one times homemade nephrolytic sera 1mL/, injects continuously to be the immunity of causing a disease in 2 days.Urine protein is detected every day in pathogenic immunity back, and after urine protein was positive, blank group, model control group gave normal saline, and polysaccharide low dose group, high dose group give anemaran respectively, and dosage sees Table 5.Once a day, equal 4 weeks of successive administration.Laboratory condition detects urine protein, total serum protein and albumin down.Experimental result sees Table 5.
Table 5: the anemaran extract is to chronic nephritis rat 24h urine protein, total serum protein and albuminous experimental result
Annotate:
△Expression is compared P＜0.05 with blank group;
△ △Expression is compared P＜0.01 with blank group;
*Expression is compared P＜0.05 with model control group;
*Expression is compared P＜0.01 with model control group
Experiment conclusion: model group and blank group relatively all have utmost point significant difference (P＜0.01), show the modeling success.Anemaran low dosage and high dose group and model group comparison 24h urine protein content significantly reduce, and total serum protein and albumin all have significant difference (P＜0.01), show that anemaran has therapeutical effect to nephrolytic sera type glomerulonephritis rat.
Experimental example 6 anemarans cause the influence of rat chronic hepatic injury to carbon tetrachloride
Get Wistar kind rat, be divided into normal control group, model control group, positive drug control group (liver adds glad group), the high, medium and low dosage group of anemaran at random.Except that the normal control group, each group 30%CCL
4Soybean oil solution is irritated stomach, secondary weekly, continuous three months.Except that normal control group and model control group, each organizes gastric infusion simultaneously: it is 400mg/kg that liver adds glad group of dosage, and the high, medium and low dosage group dosage in full side is 440mg/kg, 220mg/kg, 110mg/kg.Normal control group, model control group give with the volume distilled water, successive administration three months, fasting is 24 hours after three months, animal is plucked eyeball get blood, the concentration of glutamate pyruvate transaminase (ALT) in the detection blood and glutamic oxaloacetic transaminase, GOT (AST), total protein (TP), albumin (ALB).The results are shown in Table 2, table 3, statistical method adopts the t check.
Table 6 anemaran causes the influence (X ± SD) of chronic hepatic injury ALT, AST to CCL4
Annotate: compare with model group
*P＜0.05,
*P＜0.01
Table 6 shows: 1. to Serum ALT, the high, medium and low dosage group of anemaran all reduces by CCL significantly
4Due to the rising of ALT, but high dose group is best (P＜0.01), is dose-effect relationship; 2. to serum AST, high, medium and low dosage group can reduce by CCL significantly
4Due to the rising of AST, high dose group is best.
Table 7 anemaran is to ECL
4Cause the influence (X ± SD) of rat chronic hepatic injury TP, ALB
Annotate: compare with model group
*P＜0.05,
*P＜0.01
Table 7 shows: 1. concerning serum T P, compare the high, medium and low dosage group of the polysaccharide CCL that all can obviously raise with the model contrast
4The TP that causes reduces, but high dose is best; 2. concerning serum ALB, compare with model group, high, medium and low dosage group all has the trend of rising ALB, but no significant difference.More than the explanation anemaran has protective effect for chronic hepatic injury, can be used for the treatment of hepatitis.
Claims (5)
1. anemaran extract, it is characterized in that: the content of total polysaccharides accounts for more than 60% of extract weight percentage ratio in the described anemaran extract.
2. anemaran preparation method of extract, it is characterized in that: after the rhizoma ane marrhenae defat, obtain crude polysaccharides through water extraction, alcohol precipitation, crude polysaccharides is sloughed albumen, pigment through dialysis, ion-exchange chromatography again, remove the micromolecule chemical constituent again, make the anemaran extract of higher degree.
3. a claim 1,2 described anemaran preparation method of extract may further comprise the steps:
(1) with the Rhizoma Anemarrhenae with high concentration ethanol backflow weeding of grease solubility impurity;
(2) residue adds the water reflux, extract,, and filtrate concentrates, and adds the ethanol precipitate with ethanol, centrifugal must the precipitation;
(3) precipitation is used dehydrated alcohol respectively, and acetone washs successively;
(4) precipitation after the washing is redissolved with distilled water, dialyses;
(5) dialysis solution concentrates, and adds the ethanol precipitate with ethanol, the centrifugal polysaccharide precipitation that gets;
(6) polysaccharide precipitation is used dehydrated alcohol respectively, and acetone washs successively;
(7) polysaccharide precipitation after the washing redissolves with distilled water, and employing weak acid and weak base type anion and cation exchange resin series process is sloughed pigment and the protein in the polysaccharide, makes the anemaran extract.
4. according to claim 2,3 described anemaran preparation method of extract, it is characterized in that: in the step (1) with the Rhizoma Anemarrhenae with 80～95% alcohol reflux defats of 6～12 times of weight 2～3 times, 2～3h refluxes at every turn; The distilled water reflux, extract, 2～3 times that in the step (2) residue is added 6～12 times of weight, each reflux, extract, 2～3h is concentrated into medical material 0.2～1.0 volume with filtrate, adds 80～95% ethanol precipitate with ethanol, centrifugal must the precipitation; To precipitate the dehydrated alcohol of using 2～4 times of weight successively in step (3), (6), acetone washs respectively; Precipitation in the step (4) is redissolved with the distilled water of 0.5～2.0 times of weight, is 3.0 * 10 with the molecular weight size
3-1.2 * 10
4Bag filter dialysis 24～72h.
5. according to claim 1,2,3 described anemarans, it is characterized in that: anemaran has immunosuppressive activity, can be used for the treatment of the immunoinflammatory injury disease: the medical usage of nephritis, pneumonia, upper respiratory tract infection, hepatitis, tonsillitis and diabetes as the immunosuppressant of the various dosage forms of preparation or as the crude drug for preparing other immunosuppressive drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110087706 CN102166294B (en) | 2011-04-08 | 2011-04-08 | Common Anemarrhena asphodeloides extract with immunosuppressive activity and preparation method and medicinal purposes thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110087706 CN102166294B (en) | 2011-04-08 | 2011-04-08 | Common Anemarrhena asphodeloides extract with immunosuppressive activity and preparation method and medicinal purposes thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102166294A true CN102166294A (en) | 2011-08-31 |
| CN102166294B CN102166294B (en) | 2013-04-17 |
Family
ID=44487737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110087706 Active CN102166294B (en) | 2011-04-08 | 2011-04-08 | Common Anemarrhena asphodeloides extract with immunosuppressive activity and preparation method and medicinal purposes thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102166294B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191289A (en) * | 2013-04-08 | 2013-07-10 | 广州中医药大学 | Synchronous preparation method of four effective parts in medicine pair of common anemarrhena rhizome and amur corktree bark and application thereof |
| CN103479856A (en) * | 2013-09-22 | 2014-01-01 | 山东省医药工业研究所 | Rhizoma anemarrhenae chemical component cluster extracts and preparation process thereof |
| CN108892739A (en) * | 2018-08-13 | 2018-11-27 | 黑龙江八农垦大学 | A kind of method for extraction and purification of anemaran |
| CN110051683A (en) * | 2019-05-06 | 2019-07-26 | 广州中医药大学(广州中医药研究院) | Application of the anemaran in the drug of preparation treatment scheroma |
| CN110540603A (en) * | 2019-08-30 | 2019-12-06 | 南开大学 | Rhizoma anemarrhenae polysaccharide, and preparation method, identification method and application thereof |
| CN112480277A (en) * | 2019-09-12 | 2021-03-12 | 中国农业大学 | Process for refining and processing pleurotus ostreatus hypoglycemic polysaccharide |
| CN112876577A (en) * | 2021-03-18 | 2021-06-01 | 华南理工大学 | Homogeneous rhizoma anemarrhenae polysaccharide and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229316A (en) * | 2008-01-31 | 2008-07-30 | 广东药学院 | Rhizoma anemarrhenae extrac and applications as type 2 diabetes-curing medicine thereof |
-
2011
- 2011-04-08 CN CN 201110087706 patent/CN102166294B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101229316A (en) * | 2008-01-31 | 2008-07-30 | 广东药学院 | Rhizoma anemarrhenae extrac and applications as type 2 diabetes-curing medicine thereof |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191289A (en) * | 2013-04-08 | 2013-07-10 | 广州中医药大学 | Synchronous preparation method of four effective parts in medicine pair of common anemarrhena rhizome and amur corktree bark and application thereof |
| CN103479856A (en) * | 2013-09-22 | 2014-01-01 | 山东省医药工业研究所 | Rhizoma anemarrhenae chemical component cluster extracts and preparation process thereof |
| CN108892739A (en) * | 2018-08-13 | 2018-11-27 | 黑龙江八农垦大学 | A kind of method for extraction and purification of anemaran |
| CN110051683A (en) * | 2019-05-06 | 2019-07-26 | 广州中医药大学(广州中医药研究院) | Application of the anemaran in the drug of preparation treatment scheroma |
| CN110051683B (en) * | 2019-05-06 | 2021-07-27 | 广州中医药大学(广州中医药研究院) | Application of rhizoma anemarrhenae polysaccharide in preparing medicine for treating xerophthalmia |
| CN110540603A (en) * | 2019-08-30 | 2019-12-06 | 南开大学 | Rhizoma anemarrhenae polysaccharide, and preparation method, identification method and application thereof |
| CN110540603B (en) * | 2019-08-30 | 2021-12-24 | 南开大学 | Rhizoma anemarrhenae polysaccharide, and preparation method, identification method and application thereof |
| CN112480277A (en) * | 2019-09-12 | 2021-03-12 | 中国农业大学 | Process for refining and processing pleurotus ostreatus hypoglycemic polysaccharide |
| CN112876577A (en) * | 2021-03-18 | 2021-06-01 | 华南理工大学 | Homogeneous rhizoma anemarrhenae polysaccharide and preparation method and application thereof |
| CN112876577B (en) * | 2021-03-18 | 2022-02-22 | 华南理工大学 | Homogeneous rhizoma anemarrhenae polysaccharide and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102166294B (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102166294B (en) | Common Anemarrhena asphodeloides extract with immunosuppressive activity and preparation method and medicinal purposes thereof | |
| CN100548323C (en) | A kind of pharmaceutical composition of making by Herb Gynostemmae Pentaphylli, Radix Panacis Quinquefolii and the Radix Astragali | |
| CN110551230B (en) | Preparation method of astragalus polysaccharide | |
| CN102138981A (en) | Preparation method of plantago seed polysaccharide extractive and applications thereof | |
| CN101554409A (en) | Long pepper alkaloid and preparation method, preparation and application thereof | |
| CN102210737B (en) | Sweet potato leaf extract and preparation method and use thereof | |
| CN102772500A (en) | Relingqing Polygonum capitatum Buch-Ham ex D.Don raw material extract with anti-inflammatory action | |
| CN101348812A (en) | Lichenin, and preparation and use thereof | |
| CN102813747B (en) | Traditional Chinese medicine for treating systemic lupus erythematosus | |
| CN107778376A (en) | A kind of preparation method and applications of radix tetrastigme polysaccharide | |
| CN102225153B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and preparation method thereof | |
| CN101703537B (en) | Ephedra total polysaccharide extractive and preparation method and medical application thereof | |
| CN108210600A (en) | A kind of preparation method and applications of limonin extract | |
| CN102805767A (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN110123854B (en) | Anti-inflammatory active pharmaceutical composition based on bupleurum chinense component and application thereof | |
| CN104758334A (en) | Application of vernoniaamygdalina del leaves and vernoniaamygdalina del leaf extract in preparation of medicine used for treating diabetes | |
| CN102139002B (en) | Cortex phellodendri polysaccharide extract and preparation method and medical application thereof | |
| CN101538297A (en) | Preparation method of high-purity monomer flavone and general flavone contained in capsella bursa-pastoris and application of general flavone | |
| CN107149631A (en) | A kind of method for separating and preparing of Kwangtung purple beautyberry extract and application thereof | |
| CN101167755B (en) | Method for preparing centipede polysaccharide protein composition with anti-tumor activity and use | |
| CN105832814A (en) | General flavone with effect of treating diabetic mellitus, as well as preparation method and application thereof | |
| CN113956375A (en) | Prepared rehmannia root homogeneous polysaccharide and preparation method and anti-depression effect thereof | |
| CN101559166A (en) | Ophiopogon japonicus extract, preparation method and hypoglycemic application thereof | |
| CN103599189A (en) | Zhenqi Fuzheng (Chinese character) injection preparation and preparation method thereof | |
| CN101554382B (en) | New purpose of triterpene substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |